Be a PRO & get up to 50% off on select brands. Explore Now
you are here: HomeNewsBusiness

Zomato may invest $100 million in Grofers as e-grocer scraps listing plan: Report

Zomato's investment in Grofers is expected to value the grocery firm at $1 billion.

May 07, 2021 / 11:11 AM IST
Zomato filed its DRHP with the market regulator on April 28, stating that will offer equity shares aggregating up to Rs 8,250 crore (nearly $1.1 billion).

Zomato filed its DRHP with the market regulator on April 28, stating that will offer equity shares aggregating up to Rs 8,250 crore (nearly $1.1 billion).

Food delivery startup Zomato may invest $100 million in e-grocer Grofers after talks of a merger between the two companies fell through last year.

Maintaining focus on the food business, Zomato wants to expand into the grocery segment through a specialised company instead of building it by itself, a person privy to the deal details told the Economic Times.

Moneycontrol could not independently verify the report.

Media reports earlier suggested that Grofers was in discussions for a listing on the NASDAQ through a merger with Cantor Fitzgerald’s special purpose acquisition company (SPAC).

The Indian grocery startup now reportedly plans to scrap the listing plans. Zomato's investment in Grofers is expected to value the grocery firm at $1 billion, the publication added.

Close

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

“We are in regular touch with the investor ecosystem and are seeing a lot of inbound interest given grocery is an essential need and a high growth segment," Grofers said in an email to the publication. "Given the dynamic business environment, there will always be room for speculation, but our team is focused on serving more families."

Zomato had stepped into the grocery delivery business in the initial months of the COVID-19 pandemic but scrapped it, saying that it was not its core business.

Zomato has filed its Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) on April 28. According to the DRHP, the company will offer equity shares aggregating up to Rs 8,250 crore (nearly $1.1 Billion). Of this, Rs 7,500 crore will be fresh issue, while Rs 750 crore will be an offer for sale for its existing investor Info Edge.
Moneycontrol News
first published: May 7, 2021 11:11 am

stay updated

Get Daily News on your Browser
Sections